EP1853921B2 - Detection of a therapeutic antibody in an experimental animal - Google Patents

Detection of a therapeutic antibody in an experimental animal Download PDF

Info

Publication number
EP1853921B2
EP1853921B2 EP05824356.9A EP05824356A EP1853921B2 EP 1853921 B2 EP1853921 B2 EP 1853921B2 EP 05824356 A EP05824356 A EP 05824356A EP 1853921 B2 EP1853921 B2 EP 1853921B2
Authority
EP
European Patent Office
Prior art keywords
antibody
binding
human
therapeutic
therapeutic antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05824356.9A
Other languages
German (de)
French (fr)
Other versions
EP1853921B1 (en
EP1853921A2 (en
Inventor
Helmut Lenz
Kay-Gunnar Stubenrauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34927934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1853921(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP05824356.9A priority Critical patent/EP1853921B2/en
Priority to EP10155679A priority patent/EP2237041A1/en
Publication of EP1853921A2 publication Critical patent/EP1853921A2/en
Application granted granted Critical
Publication of EP1853921B1 publication Critical patent/EP1853921B1/en
Publication of EP1853921B2 publication Critical patent/EP1853921B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig

Definitions

  • the present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal.
  • the present invention relates to a method of detecting a human or humanized therapeutic monoclonal antibody which is intended for use in a human being in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to said therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to
  • Mammals usually have between about 10 to about 30 milligram of immunoglobulin per ml in the circulation.
  • Therapeutic monoclonal antibodies typically have to be tested with serum levels ranging from about between 1 nanogram per ml to about 100 microgram per ml.
  • the therapeutic antibody thus has to be detected against a background of host antibodies which is in an excess of about 100-fold to 10 million-fold.
  • the detection of a human or humanized therapeutic antibody in the background of host immunoglobulin represents quite a significant task to the pharmacologist.
  • different therapeutic antibodies may require different reagents and assay formats. The detection of a human or humanized antibody becomes more and more difficult the closer the test animal is related to H. sapiens.
  • the present invention relates to a method of detecting a human or humanized therapeutic monoclonal antibody which is intended for use in a human being in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to said therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708.
  • therapeutic antibody relates to any antibody preparation which is intended for use in a human being.
  • therapeutic antibody will be a monoclonal antibody.
  • monoclonal antibody will be obtained from a great ape or be a human monoclonal antibody.
  • it will be a human monoclonal antibody.
  • therapeutic monoclonal antibody will be a humanized monoclonal antibody.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Koehler, G., et al., Nature 256 (1975) 495-497 , or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567 ).
  • the "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson, T., et al., Nature 352 (1991) 624-628 and Marks, J. D., et al., J. Mol. Biol. 222 (1991) 581-597 , for example.
  • Humanized forms of non-human (e.g., rodent) antibodies are chimaeric antibodies that contain partial sequences derived from non-human immunoglobulin and from a human immunoglobulin.
  • humanized antibodies are derived from a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity and affinity.
  • donor antibody such as mouse, rat, rabbit or non-human primate having the desired specificity and affinity.
  • framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise further modifications, e.g., amino acid residues that are not found in the recipient antibody or in the donor antibody. Such modifications result in variants of such recipient or donor antibody which are homologous but not identical to the corresponding parent sequence. These modifications are made to further refine antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human donor antibody and all or substantially all of the FRs are those of a human recipient antibody.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain.
  • Humanization can be essentially performed following the method of Winter and co-workers ( Jones, P.T., et al., Nature 321 (1986) 522-525 ; Riechmann, L., et al., Nature, 332 (1988) 323-327 ; Verhoeyen, M., et al., Science, 239 (1988) 1534-1536 and Presta, L.G., Curr. Op.
  • humanized antibodies are chimaeric antibodies ( U.S. Patent No. 4,816,567 ), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
  • the human sequence which is closest to that of the rodent is then accepted as the human framework region (FR) for the humanized antibody ( Sims, M.J., et al., J. Immunol., 151 (1993) 2296-2308 ; Chothia, C., et al., J. Mol. Biol. 196 (1987) 901-917 ).
  • Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
  • the same framework may be used for several different humanized antibodies ( Carter, P., et al., Proc. Natl. Acad. Sci. USA, 89 (1992) 4285-4289 ; Presta, L.G., et al., J. Immunol. 151 (1993) 2623-2632 ).
  • humanized therapeutic antibodies are the so-called anti-ErbB2 antibodies including huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as described in Table 3 of U.S. Patent 5,821,337 ; as well as humanized 520C9 (described in WO 93/21319 ) and humanized 2C4 antibodies as described in WO 2004/008099 .
  • anti-ErbB2 antibodies including huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as described in Table
  • variant refers to polypeptides having amino acid sequences that differ to some extent from a native polypeptide sequence.
  • a variant amino acid sequence variant will possess at least about 80% homology with the corresponding parent antibody sequence, and preferably, they will be at least about 90%, more preferably at least about 95% homologous with such corresponding parent antibody sequence.
  • the amino acid sequence variants possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence of the native amino acid sequence.
  • “Homology” is defined as the percentage of residues in the amino acid sequence variant that are identical after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. One such computer program is " Align 2", authored by Genentech, Inc., which was filed with user documentation in the United States Copyright Office, Washington, DC 20559, on December 10, 1991 .
  • experimental animal denotes the members of the families of the order of primates comprising marmosets and tamarins (family Callitrichidae), new world monkeys (family Cebidae), old world monkeys (family Cercopithecidae), dwarf and mouse lemurs (family Cheirogaleidae), aye-aye (family Daubentoniidae), bushbabies and galagos (family Galagonidae), gibbons and lesser apes (family Hylobatidae), indris, sifakas, and relatives (family Indridae), true lemurs (family Lemuridae), lorises (family Loridae), university lemurs (family Megaladapidae), tarsiers (family Tarsiidae), as well as crossings thereof.
  • family Callitrichidae family Cebidae
  • old world monkeys family Cercopithecidae
  • dwarf and mouse lemurs family
  • the method according to the present invention will be practiced in experimental animals selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof.
  • the great apes especially the group of chimpanzees, bonobos, gorillas and orangutans is excluded.
  • sample may be any tissue or liquid sample removed from the experimental animal.
  • the sample will be a liquid sample like Saliva, urine, whole blood, plasma or serum.
  • the sample will be whole blood, plasma or serum.
  • binding properties of an antibody especially the KDiss., preferably is assessed by a Biacore® instrument.
  • binding properties are evaluated by changes in surface plasmon resonance (SPR). It is convenient to bind the antibody under investigation to the solid phase (called chip) and to assess binding of a monoclonal antibody, a polyclonal antibody or even of serum comprising IgG to this coated chip.
  • SPR surface plasmon resonance
  • the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal under investigation may be a monoclonal antibody, fragments of such antibodies, as well as genetic constructs comprising the binding domain of such antibody. Any antibody fragment retaining the above criteria of binding to the human or humanized therapeutic monoclonal antibody and of non-binding to the immunoglobulin of said experimental animal can be used.
  • Antibodies as well as antibody fragments are generated by state of the art procedures, e.g., as described in Tijssen ( Tijssen, P., Practice and theory of enzyme immunoassays 11 (1990), the whole book, especially pages 43-78, Elsevier, Amsterd am).
  • a therapeutic antibody in an experimental animal may have to be assessed during pre-clinical studies. In certain settings it may be relevant to analyze the total amount of therapeutic antibody present, or it may be important to analyze certain modifications of a therapeutic antibody, the concentration of therapeutic antibody bound to an antigen or the fraction of therapeutic antibody still capable of binding to an antigen.
  • the method according to the present invention is used to detect the total, active, or antigen-bound therapeutic antibody.
  • total therapeutic antibody refers to any antibody detected irrespective of whether the antibody is active (i.e., still reactive with its antigen), inactive, and/or antigen-bound.
  • active therapeutic antibody relates to the therapeutic antibody present in an experimental animal that still is capable of binding its antigen. Such antibodies, e.g., have not bound its antigen or any other molecule at its antigen binding site.
  • antigen-bound therapeutic antibody is used to indicate the therapeutic antibody as present in the circulation of an experimental animal that is bound to its antigen.
  • Total, active or antigen-bound therapeutic antibody as defined above can be detected in a method according to the present invention.
  • inactive therapeutic antibody may, e.g., be a therapeutic antibody bound to its antigen, the therapeutic antibody bound to a cross-reactive antigen, or the therapeutic antibody blocked by an auto antibody against the therapeutic antibody.
  • inactive therapeutic antibody may, e.g., be a therapeutic antibody bound to its antigen, the therapeutic antibody bound to a cross-reactive antigen, or the therapeutic antibody blocked by an auto antibody against the therapeutic antibody.
  • Various assay systems are at hand to analyze e.g., total, active or antigen-bound therapeutic antibody.
  • Total antibody for example can be detected in a so-called competitive immunoassay system or in a so-called sandwich type assay system.
  • Such assay may be performed without washing steps (homogeneous immunoassay) or with washing steps (heterogeneous immunoassay).
  • total therapeutic antibody is detected in a sandwich type immunoassay, wherein the antibody which is binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal is used at both sides of such sandwich assay.
  • the antibody used at one side of such sandwich is bound or capable of binding to a solid phase (often referred to as capture antibody), whereas the antibody at the other side of such sandwich is labeled in such a manner that direct or indirect detection is facilitated (so-called detection antibody).
  • detection antibody the amount of detection antibody bound in such sandwich assay procedure is directly correlated to the amount of therapeutic antibody in the sample investigated.
  • Detection of active therapeutic antibody in a sample may be achieved by convenient state of the art procedures.
  • the detection of total therapeutic antibody or of the fraction of therapeutic antibody bound to its antigen is rather complicated and requires quite different assay set-ups and especially requires tailor-made reagents for each of the different assays.
  • With the antibody that is binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal it is possible to assess the fraction of active therapeutic antibody, total therapeutic antibody, or antigen-bound therapeutic antibody as claimed in test systems which are analogues to each other.
  • this kind of comparative assessment of total, active, or antigen-bound therapeutic antibody should have big advantages once quantitative comparisons are made in between these various fractions of therapeutic antibody.
  • a sandwich type assay format is (also) set up to detect the active therapeutic antibody.
  • the antibody which is binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal is used as a capture antibody and the detection side of such sandwich assay either makes use of the antigen in a labeled form or after binding of the antigen makes use of a second antibody not binding to or competing with the epitope recognized by the therapeutic antibody, wherein said second antibody is specifically detectable and/or is labeled in such a manner that direct or indirect detection is facilitated.
  • the antigen-bound therapeutic antibody preferably is detected in a sandwich type assay format again preferably using the antibody binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal as a capture reagent.
  • a second antibody is used binding to the antigen at an epitope which does not compete with the epitope of the therapeutic antibody.
  • Said second antibody preferably is labeled in such a manner that direct or indirect detection is facilitated.
  • the labeling group can be selected from any known detectable marker groups, such as dyes, luminescent labeling groups such as chemiluminescent groups, e.g. acridinium esters or dioxetanes, or fluorescent dyes, e.g. fluorescein, coumarin, rhodamine, oxazine, resorufin, cyanine and derivatives thereof.
  • Other examples of labeling groups are luminescent metal complexes, such as ruthenium or europium complexes, enzymes, e.g. as used for ELISA or for CEDIA (Cloned Enzyme Donor Immunoassay, e.g. EP-A-0 061 888 ), and radioisotopes.
  • Indirect detection systems comprise, for example, that the detection reagent, e.g., the detection antibody is labeled with a first partner of a bioaffine binding pair.
  • suitable binding pairs are hapten or antigen/antibody, biotin or biotin analogues such as aminobiotin, iminobiotin or desthiobiotin/avidin or streptavidin, sugar/lectin, nucleic acid or nucleic acid analogue/complementary nucleic acid, and receptor/ligand, e.g., steroid hormone receptor/steroid hormone.
  • Preferred first binding pair members comprise hapten, antigen and hormone. Especially preferred are haptens like digoxin and biotin and analogues thereof.
  • the second partner of such binding pair e.g. an antibody, streptavidin, etc., usually is labeled to allow for direct detection, e.g., by the labels as mentioned above.
  • Immunoassays are well known to the skilled artisan. Methods for carrying out such assays as well as practical applications and procedures are summarized in related textbooks. Examples of related textbooks are Tijssen, P., Preparation of enzyme-antibody or other enzyme-macromolecule conjugates (in: " Practice and theory of enzyme immunoassays” (1990), pp. 221-278, Eds. R.H. Burdon and v. P.H. Knippenberg, Elsevier, Amsterd am) and various volumes of " Methods in Enzymology” (Eds. S.P. Colowick, N.O. Caplan, Academic Press ), dealing with immunological detection methods, especially volumes 70, 73, 74, 84, 92 and 121.
  • reagent conditions are chosen which allow for binding of the reagents employed, e.g. for binding of an antibody to its corresponding antigen.
  • the skilled artisan refers to the result of such binding event by using the term complex.
  • the complex formed in an assay method according to the present invention is correlated by state of the art procedures to the corresponding concentration of said therapeutic antibody. Depending on the detection reagent employed this correlating step will result in the concentration of total, active or antigen-bound therapeutic antibody.
  • the methods according to the present invention can not only reveal the concentrations of total, antigen-bound, active or even inactive therapeutic antibody. Due to the preferred use of one and the same reagent, the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of said experimental animal, in the different assays the values obtained can be easily compared to each other and even ratios thereof assessed.
  • the present disclosure also relates to the ratio of active to total therapeutic antibody. This ratio may well serve as an indicator for the efficacy of a therapeutic antibody.
  • a monoclonal antibody that binds to a therapeutic antibody that monoclonal antibody having an antigen combining site which competitively inhibits the binding of monoclonal antibody MAB M-R10Z8E9 as produced by this hybridoma deposited with the DSMZ.
  • the term "competitively inhibits” means being able to recognize and bind the epitope as recognized by monoclonal antibody M-R10Z8E9. Such binding is easily assessed using conventional reciprocal antibody competition assays.
  • Biacore® system see above. Binding of an antibody under investigation to the same epitope as bound by MAB M-R10Z8E9 is present if the antibody under investigation at equimolar concentration reduces the binding of MAB M-R10Z8E9 to human IgG by 20% or more and if MAB M-R10Z8E9 reduces the binding of said antibody to human IgG by 20% or more.
  • MAB M-R10Z8E9 is used as the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal in a method according to the present invention.
  • the therapeutic antibody detected in a method according the present invention is a human or a humanized monoclonal antibody.
  • the therapeutic antibody used in a method according to the present invention comprises the epitope as bound by MAB M-R10Z8E9.
  • the present invention relates to the use of an antibody which is binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of an experimental animal for measuring the concentration of total, active, or antigen-bound therapeutic antibody in a sample obtained from an experimental animal.
  • the antibody used in such method is the antibody MAB M-R10Z8E9.
  • a microtiter plate (MTP) (Maxisorb®, Nunc) was coated with monkey (e.g. cynomolgus) and with human serum diluted to 20% in carbonate buffer (pH 9.6), at room temperature (RT) for 1 hour, respectively. After washing 3 times with PBS-Tween®20, all wells of the MTPs were blocked with PBS/3%BSA at room temperature for 1 hour. Then the wells of the MTPs were incubated (1 h; RT) with different anti-human IgG antibodies (un-conjugated, or anti-human IgG antibody horseradish peroxidase (POD) conjugates (see Table 1)). The various anti-human antibodies were used as recommended by the corresponding manufacturer.
  • monkey e.g. cynomolgus
  • human serum diluted to 20% in carbonate buffer (pH 9.6), at room temperature (RT) for 1 hour, respectively.
  • PBS-Tween®20 After washing 3 times with PBS-Tween®
  • Wells were washed three times as above. Wells incubated with POD-conjugates were directly processed for enzymatic reaction/detection of bound anti-human immunoglobulin. The other wells were incubated (1 h; RT) as appropriate with anti-Dig-, anti-mouse IgG- or streptavidin-POD-conjugates (all reagents from Roche Diagnostics, Germany) followed by a washing step. The POD comprised in the POD-conjugates catalyzes the color reaction of ABTS substrate. The signal was measured by an ELISA reader at a wavelength of 405 nm (reference wavelength: 490 nm).
  • the high signal ratio for human serum as compared to cynomolgus serum observed for MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 indicates the high human-specificity of MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9.
  • MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 all other tested antibodies show a high cross-reactivity.
  • MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 exclusively reacts with the immunoglobulin of human serum human IgG or chimpanzee serum respectively.
  • a saturating amount of MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 and polyclonal anti-human Fc ⁇ antibody (Dianova), respectively, was immobilized by amine coupling on different channels of the same CM5-chip. All animal sera were diluted in HBS buffer containing 1mg/ml CM-dextran at a final concentration of 1%. Binding was analyzed by injection of the 1 in 100 diluted sera and incubation for 60 seconds. Dissociation was measured by washing the chip surface with HBS buffer for 180 seconds. Using Biaevaluation Software from Biacore® the dissociation constant values ( KDiss.) were calculated with a 1:1 Langmuir fitting model.
  • the SPR-analysis confirms the results seen in the MTP ELISA.
  • MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 does not cross-react with any monkey species. Only the IgG comprised in human and chimpanzee (greater ape) serum is detected. In contrast to the MTP ELISA some binding of dog serum to MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9.
  • the relatively high KDiss. for dog IgG (correlating to inferior binding) as compared to human IgG with a KDiss.-gap of more than 100-fold indicates, that this low interaction does not interfere significantly in an immunoassay. This is actually what has been found in the MTP ELISA of Example 1a).
  • polyclonal anti-human Fc antibody shows a high cross-reactivity with sera of dog and all tested monkey species.
  • Biotinylated MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 or polyclonal antibody directed against human Fc was bound to streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound antibody was removed by washing. Samples/standards, e.g. MAB ⁇ IGF-1R> spiked in cynomolgus serum, were simultaneously preincubated with digoxigenylated MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 - DIG) for 1 hour. Afterwards the mixture was added to wells of an SA-MTP coated with the biotinylated ⁇ human IgG> antibodies and incubated for 1 hour.
  • SA-MTP streptavidin-coated microtiter plates
  • Table 3 Comparison of standard curve in buffer (PBS-T, 0.5% BSA) concentration of MAB ⁇ IGF-1R> [ng/ml] signal OD 405 nm *MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 10 2.039 1.937 5 1.109 1.094 2.5 0.586 0.593 1.25 0.296 0.326 0.625 0.170 0.176 0.313 0.108 0.106 0.156 0.075 0.068 0 0.046 0.027
  • Table 4 Comparison of standard curves in 5% cynomolgus serum concentration of MAB ⁇ IL-1R> [ng/ml] signal OD 405 nm MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 10 1.990 1.5230 5 1.057 1.4335 2.5 0.559 1.4410 1.25 0.289 1.3840 0.625 0.166 1.3610 0.313 0.108 1.3780 0.156 0.091 1.3170 0 0.054 1.3870
  • Biotinylated soluble human IL-1 receptor (h-IL-1R-Bi) was bound to streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound receptor was removed by washing. Afterwards MAB ⁇ IL-1R> spiked in cynomolgus serum was bound to the immobilized human IL-1 receptor.
  • the bound MAB ⁇ IL-1R> was detected with a) digoxigenylated monoclonal antibody against human IgG chains (MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9-DIG) followed by incubation with a horse-radish peroxidase labeled anti-Digoxigenin-antibody; or with b) polyclonal anti-human Fc antibodies (Dianova) followed by a wash step.
  • the POD comprised in the antibody-enzyme conjugates catalyzes the color reaction of ABTS substrate.
  • the signal is measured by ELISA reader at 405 nm wavelength (reference wavelength: 490 nm). Absorbance values of each serum sample are determined in triplicates.
  • Table 5 Detection of total therapeutic antibody concentration of MAB ⁇ IL-1R> [ng/ml] signal OD 405 nm MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 10 1.921 1.682 5 1.307 0.933 2.5 0.770 0.489 1.25 0.424 0.262 0.625 0.231 0.143 0.313 0.125 0.084 0.156 0.074 0.057 0 0.020 0.031
  • Table 6 Detection of total therapeutic antibody in cynomolgus Serum concentration of MAB ⁇ IL-1R> [ng/ml] signal OD 405 nm MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 10 1.642 1.789 5 1.637 1.608 2.5 1.272 1.400 1.25 0.755 1.228 0.625 0.435 1.419 0.313 0.236 1.331 0.156 0.128 1.3
  • Biotinylated MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 or biotinylated polyclonal anti-human IgG directed against human Fc (b) was bound onto the wells of a streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound antibody was removed by washing. Afterwards the MAB ⁇ IL-1R> spiked into cynomolgus serum was bound to the immobilized anti-human antibody.
  • SA-MTP streptavidin-coated microtiter plates
  • the bound MAB ⁇ IL-1R> was detected with digoxigenylated soluble human IL-1 receptor (h-IL-1R-Dig) followed by incubation with a horse-radish peroxidase labeled anti-digoxigenin-antibody.
  • the antibody-enzyme conjugate catalyzes the color reaction of ABTS substrate.
  • the signal is measured by ELISA reader at 405 nm wavelength (reference wavelength: 490 nm). Absorbance values of each serum sample are determined in triplicates.
  • Table 7 Comparison of the standard curves in buffer (PBS-T, 0.5% BSA) concentration of MAB ⁇ IL-1R> [ng/ml] signal OD 405 nm MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 5 1.824 1.685 2.5 1.319 1.112 1.25 0.837 0.702 0.625 0.497 0.413 0.313 0.277 0.229 0.156 0.159 0.132 0 0.025 0.032
  • Table 8 Comparison of the standard curves in 5% cynomolgus serum concentration of MAB ⁇ IL-1R> [ng/ml] signal OD 405 nm MAB ⁇ H-Fc ⁇ pan>M-R10Z8E9 PAB ⁇ H-Fc ⁇ > (Dianova) 5 1.635 0.805 2.5 1.179 0.460 1.25 0.707 0.278 0.625 0.421 0.163 0.313

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention discloses a method of detecting a therapeutic antibody in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to a therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody.

Description

  • The present invention relates to the field of therapeutic antibodies. It especially relates to the study of therapeutic antibodies in an experimental animal. The present invention relates to a method of detecting a human or humanized therapeutic monoclonal antibody which is intended for use in a human being in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to said therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708. It also relates to the use of an antibody which is binding to a human or humanized therapeutic monoclonal antibody which is intended for use in a human being and not binding to the immunoglobulin of an experimental animal for measuring the concentration of total, active, or antigen-bound therapeutic antibody in a sample obtained from an experimental animal, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708.
  • Since the development of the first monoclonal antibodies by Koehler and Milstein in 1974 a lot of efforts have been dedicated to the development of antibodies which are appropriate for therapy in humans. The first monoclonal antibodies which became available had been developed in mice and rats. These antibodies when used for therapy of a human being caused unwanted side effects due to anti-rodent antibodies. A lot of efforts have been dedicated to the reduction or even elimination of such unwanted side effects.
  • In the past ten years an ever growing number of human monoclonal antibodies or humanized monoclonal antibodies have reached the market. Well-known examples include for example Herceptin® and MabThera® from Hoffmann-La Roche, Basel.
  • A quite significant number of human or humanized monoclonal antibodies is under investigation and needs to be studied in experimental animals, before entry into human can be considered for the first trial purposes.
  • Important criteria like bio-availability and antibody clearance just to mention two of them have to be studied by the aid of experimental animals. Many of these studies require the quantification of the therapeutic antibody in the background of the host's own antibodies. In most cases mammals are used as experimental animals. Toxicology often is first assessed in rodents like mice or rats. In the more advanced stages of drug development, especially before entry of the drug into human beings, even monkeys have to be included into such pre-clinical studies.
  • Mammals usually have between about 10 to about 30 milligram of immunoglobulin per ml in the circulation.
  • Therapeutic monoclonal antibodies typically have to be tested with serum levels ranging from about between 1 nanogram per ml to about 100 microgram per ml. The therapeutic antibody thus has to be detected against a background of host antibodies which is in an excess of about 100-fold to 10 million-fold. The detection of a human or humanized therapeutic antibody in the background of host immunoglobulin represents quite a significant task to the pharmacologist. In addition it will be appreciated that different therapeutic antibodies may require different reagents and assay formats. The detection of a human or humanized antibody becomes more and more difficult the closer the test animal is related to H. sapiens.
  • In US 2004/214761 methods for treating multiple myeloma are reported. That human melanoma-associated retinopathy antibodies alter the retinal own-response of the monkey ERG in vivo is reported by Lei, B., et al. in Invest. Ophthalmol. Vis. Sci. 41 (2000) 262-266. Hazelwood, M., et al. (Clin. Exp. Immunol. 93 (1993) 157-164) report the acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK. The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site is reported by Nath, D., et al. (J. Biol. Chem. 270 (1995) 26184-26191). In EP 1 098 198 a method for the qualitative and quantitative determination of class IgG human antibodies is reported.
  • It was a task of the present invention to investigate whether methods of detecting a therapeutic antibody in a sample obtained from an experimental animal can be improved. It was also investigated whether a human or a humanized therapeutic antibody can be studied in sera of monkeys, especially in sera of lesser apes. This task has been accomplished by the invention as described below and in the examples section and as claimed in the appending claims.
  • In a first embodiment the present invention relates to a method of detecting a human or humanized therapeutic monoclonal antibody which is intended for use in a human being in a sample obtained from an experimental animal comprising the steps of a) providing the sample to be analyzed, b) incubating said sample with an antibody binding to said therapeutic antibody and not binding to the immunoglobulin of said experimental animal, c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708.
  • The term "therapeutic antibody" relates to any antibody preparation which is intended for use in a human being. Preferably such therapeutic antibody will be a monoclonal antibody. Further preferred such monoclonal antibody will be obtained from a great ape or be a human monoclonal antibody. Preferably, it will be a human monoclonal antibody. Also preferred such therapeutic monoclonal antibody will be a humanized monoclonal antibody.
  • The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Koehler, G., et al., Nature 256 (1975) 495-497, or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567 ). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson, T., et al., Nature 352 (1991) 624-628 and Marks, J. D., et al., J. Mol. Biol. 222 (1991) 581-597, for example.
  • "Humanized" forms of non-human (e.g., rodent) antibodies are chimaeric antibodies that contain partial sequences derived from non-human immunoglobulin and from a human immunoglobulin. For the most part, humanized antibodies are derived from a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity and affinity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise further modifications, e.g., amino acid residues that are not found in the recipient antibody or in the donor antibody. Such modifications result in variants of such recipient or donor antibody which are homologous but not identical to the corresponding parent sequence. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human donor antibody and all or substantially all of the FRs are those of a human recipient antibody. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Methods for humanizing non-human antibodies have been described in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones, P.T., et al., Nature 321 (1986) 522-525; Riechmann, L., et al., Nature, 332 (1988) 323-327; Verhoeyen, M., et al., Science, 239 (1988) 1534-1536 and Presta, L.G., Curr. Op. Struct. Biol., 2 (1992) 593-596), by substituting hypervariable region sequences for the corresponding sequences of a non-human antibody. Accordingly, such "humanized" antibodies are chimaeric antibodies ( U.S. Patent No. 4,816,567 ), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework region (FR) for the humanized antibody (Sims, M.J., et al., J. Immunol., 151 (1993) 2296-2308; Chothia, C., et al., J. Mol. Biol. 196 (1987) 901-917). Another method uses a particular framework region derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter, P., et al., Proc. Natl. Acad. Sci. USA, 89 (1992) 4285-4289; Presta, L.G., et al., J. Immunol. 151 (1993) 2623-2632).
  • Well known examples of humanized therapeutic antibodies are the so-called anti-ErbB2 antibodies including huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN®) as described in Table 3 of U.S. Patent 5,821,337 ; as well as humanized 520C9 (described in WO 93/21319 ) and humanized 2C4 antibodies as described in WO 2004/008099 .
  • The term "variant" refers to polypeptides having amino acid sequences that differ to some extent from a native polypeptide sequence. Ordinarily, a variant amino acid sequence variant will possess at least about 80% homology with the corresponding parent antibody sequence, and preferably, they will be at least about 90%, more preferably at least about 95% homologous with such corresponding parent antibody sequence. The amino acid sequence variants possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence of the native amino acid sequence.
  • "Homology" is defined as the percentage of residues in the amino acid sequence variant that are identical after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. One such computer program is " Align 2", authored by Genentech, Inc., which was filed with user documentation in the United States Copyright Office, Washington, DC 20559, on December 10, 1991 .
  • The term "experimental animal" as used herein denotes the members of the families of the order of primates comprising marmosets and tamarins (family Callitrichidae), new world monkeys (family Cebidae), old world monkeys (family Cercopithecidae), dwarf and mouse lemurs (family Cheirogaleidae), aye-aye (family Daubentoniidae), bushbabies and galagos (family Galagonidae), gibbons and lesser apes (family Hylobatidae), indris, sifakas, and relatives (family Indridae), true lemurs (family Lemuridae), lorises (family Loridae), sportive lemurs (family Megaladapidae), tarsiers (family Tarsiidae), as well as crossings thereof.
  • Thus the method according to the present invention will be practiced in experimental animals selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof. In this embodiment the closest relatives to mankind, the great apes, especially the group of chimpanzees, bonobos, gorillas and orangutans is excluded.
  • A "sample" according to the present invention may be any tissue or liquid sample removed from the experimental animal. Preferably the sample will be a liquid sample like Saliva, urine, whole blood, plasma or serum. Preferably the sample will be whole blood, plasma or serum.
  • An "antibody binding to a therapeutic antibody and not binding to the immunoglobulin of an experimental animal" will bind to a therapeutic antibody with a dissociation constant (=KDiss.) of at least 10-9 mol/L, more preferred with a KDiss. of at least 10-10 mol/L. At the same time the property of not binding to the immunoglobulin of the experimental animal is insured by a KDiss. of 10-8 mol/L or worse. Also preferred, the antibody binding to a therapeutic antibody and not binding to the immunoglobulin of an experimental animal will have a KDiss.-gap of at least 100-fold between its reactivity towards the IgG of an experimental animal and towards human IgG, respectively.
  • The binding properties of an antibody, especially the KDiss., preferably is assessed by a Biacore® instrument. In this method binding properties are evaluated by changes in surface plasmon resonance (SPR). It is convenient to bind the antibody under investigation to the solid phase (called chip) and to assess binding of a monoclonal antibody, a polyclonal antibody or even of serum comprising IgG to this coated chip.
  • The antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal under investigation may be a monoclonal antibody, fragments of such antibodies, as well as genetic constructs comprising the binding domain of such antibody. Any antibody fragment retaining the above criteria of binding to the human or humanized therapeutic monoclonal antibody and of non-binding to the immunoglobulin of said experimental animal can be used. Antibodies as well as antibody fragments are generated by state of the art procedures, e.g., as described in Tijssen (Tijssen, P., Practice and theory of enzyme immunoassays 11 (1990), the whole book, especially pages 43-78, Elsevier, Amsterdam).
  • As indicated further above, various aspects connected to the application of a therapeutic antibody in an experimental animal may have to be assessed during pre-clinical studies. In certain settings it may be relevant to analyze the total amount of therapeutic antibody present, or it may be important to analyze certain modifications of a therapeutic antibody, the concentration of therapeutic antibody bound to an antigen or the fraction of therapeutic antibody still capable of binding to an antigen. Optionally, the method according to the present invention is used to detect the total, active, or antigen-bound therapeutic antibody.
  • The term "total" therapeutic antibody refers to any antibody detected irrespective of whether the antibody is active (i.e., still reactive with its antigen), inactive, and/or antigen-bound.
  • The term "active" therapeutic antibody relates to the therapeutic antibody present in an experimental animal that still is capable of binding its antigen. Such antibodies, e.g., have not bound its antigen or any other molecule at its antigen binding site.
  • The term "antigen-bound" therapeutic antibody is used to indicate the therapeutic antibody as present in the circulation of an experimental animal that is bound to its antigen.
  • Total, active or antigen-bound therapeutic antibody as defined above can be detected in a method according to the present invention.
  • In addition, it is also possible to indirectly assess any "inactive" therapeutic antibody. Such inactive therapeutic antibody may, e.g., be a therapeutic antibody bound to its antigen, the therapeutic antibody bound to a cross-reactive antigen, or the therapeutic antibody blocked by an auto antibody against the therapeutic antibody. As the skilled artisan will appreciate, it is possible by aid of the present disclosure to assess the fraction of inactive antibody. In case the total antibody amounts to more than the sum of active antibody and antigen-bound antibody, an additional fraction of antibody comprising the inactive antibody not bound to its corresponding antigen will be present.
  • Various assay systems are at hand to analyze e.g., total, active or antigen-bound therapeutic antibody.
  • Total antibody for example can be detected in a so-called competitive immunoassay system or in a so-called sandwich type assay system.
  • Such assay may be performed without washing steps (homogeneous immunoassay) or with washing steps (heterogeneous immunoassay).
  • Preferably total therapeutic antibody is detected in a sandwich type immunoassay, wherein the antibody which is binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal is used at both sides of such sandwich assay. The antibody used at one side of such sandwich is bound or capable of binding to a solid phase (often referred to as capture antibody), whereas the antibody at the other side of such sandwich is labeled in such a manner that direct or indirect detection is facilitated (so-called detection antibody). The amount of detection antibody bound in such sandwich assay procedure is directly correlated to the amount of therapeutic antibody in the sample investigated.
  • In the art (e.g. US 2003/0068664 ) assay systems are known, which allow for the detection of active therapeutic antibodies. Such systems require the binding of the antigen to a solid phase, binding of the therapeutic antibody to this bound antigen and detection of the therapeutic antibody bound via the antigen to the solid phase.
  • Detection of active therapeutic antibody in a sample may be achieved by convenient state of the art procedures. However, the detection of total therapeutic antibody or of the fraction of therapeutic antibody bound to its antigen is rather complicated and requires quite different assay set-ups and especially requires tailor-made reagents for each of the different assays. With the antibody that is binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal it is possible to assess the fraction of active therapeutic antibody, total therapeutic antibody, or antigen-bound therapeutic antibody as claimed in test systems which are analogues to each other. By its very nature this kind of comparative assessment of total, active, or antigen-bound therapeutic antibody should have big advantages once quantitative comparisons are made in between these various fractions of therapeutic antibody.
  • Preferably a sandwich type assay format is (also) set up to detect the active therapeutic antibody. Preferably, the antibody which is binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal is used as a capture antibody and the detection side of such sandwich assay either makes use of the antigen in a labeled form or after binding of the antigen makes use of a second antibody not binding to or competing with the epitope recognized by the therapeutic antibody, wherein said second antibody is specifically detectable and/or is labeled in such a manner that direct or indirect detection is facilitated.
  • The antigen-bound therapeutic antibody preferably is detected in a sandwich type assay format again preferably using the antibody binding to a therapeutic antibody and not binding to the immunoglobulin of the experimental animal as a capture reagent. In the detection preferably a second antibody is used binding to the antigen at an epitope which does not compete with the epitope of the therapeutic antibody. Said second antibody preferably is labeled in such a manner that direct or indirect detection is facilitated.
  • For direct detection the labeling group can be selected from any known detectable marker groups, such as dyes, luminescent labeling groups such as chemiluminescent groups, e.g. acridinium esters or dioxetanes, or fluorescent dyes, e.g. fluorescein, coumarin, rhodamine, oxazine, resorufin, cyanine and derivatives thereof. Other examples of labeling groups are luminescent metal complexes, such as ruthenium or europium complexes, enzymes, e.g. as used for ELISA or for CEDIA (Cloned Enzyme Donor Immunoassay, e.g. EP-A-0 061 888 ), and radioisotopes.
  • Indirect detection systems comprise, for example, that the detection reagent, e.g., the detection antibody is labeled with a first partner of a bioaffine binding pair. Examples of suitable binding pairs are hapten or antigen/antibody, biotin or biotin analogues such as aminobiotin, iminobiotin or desthiobiotin/avidin or streptavidin, sugar/lectin, nucleic acid or nucleic acid analogue/complementary nucleic acid, and receptor/ligand, e.g., steroid hormone receptor/steroid hormone. Preferred first binding pair members comprise hapten, antigen and hormone. Especially preferred are haptens like digoxin and biotin and analogues thereof. The second partner of such binding pair, e.g. an antibody, streptavidin, etc., usually is labeled to allow for direct detection, e.g., by the labels as mentioned above.
  • Immunoassays are well known to the skilled artisan. Methods for carrying out such assays as well as practical applications and procedures are summarized in related textbooks. Examples of related textbooks are Tijssen, P., Preparation of enzyme-antibody or other enzyme-macromolecule conjugates (in: "Practice and theory of enzyme immunoassays" (1990), pp. 221-278, Eds. R.H. Burdon and v. P.H. Knippenberg, Elsevier, Amsterdam) and various volumes of "Methods in Enzymology" (Eds. S.P. Colowick, N.O. Caplan, Academic Press), dealing with immunological detection methods, especially volumes 70, 73, 74, 84, 92 and 121.
  • In all the above immunological detection methods reagent conditions are chosen which allow for binding of the reagents employed, e.g. for binding of an antibody to its corresponding antigen. The skilled artisan refers to the result of such binding event by using the term complex. The complex formed in an assay method according to the present invention is correlated by state of the art procedures to the corresponding concentration of said therapeutic antibody. Depending on the detection reagent employed this correlating step will result in the concentration of total, active or antigen-bound therapeutic antibody.
  • As the skilled artisan will appreciate the methods according to the present invention can not only reveal the concentrations of total, antigen-bound, active or even inactive therapeutic antibody. Due to the preferred use of one and the same reagent, the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of said experimental animal, in the different assays the values obtained can be easily compared to each other and even ratios thereof assessed. The present disclosure also relates to the ratio of active to total therapeutic antibody. This ratio may well serve as an indicator for the efficacy of a therapeutic antibody.
  • During the course of the experiments leading to the present invention it has been found that a certain epitope that is present on all classes of human immunoglobulin of class G appears not to be present on the immunoglobulin of any experimental animal except on the IgG of chimpanzees. This epitope is characterized by its binding to MAB<H-Fcγ pan>M-R10Z8E9, also denoted MAB<h-Fc gamma>M-R10Z8E9, or briefly MAB M-R10Z8E9. According to the present invention the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of an experimental animal is MAB M-R10Z8E9, deposited with DSMZ on December 22, 2004 in DSM ACC2708.
  • Also disclosed is a monoclonal antibody that binds to a therapeutic antibody that monoclonal antibody having an antigen combining site which competitively inhibits the binding of monoclonal antibody MAB M-R10Z8E9 as produced by this hybridoma deposited with the DSMZ. The term "competitively inhibits" means being able to recognize and bind the epitope as recognized by monoclonal antibody M-R10Z8E9. Such binding is easily assessed using conventional reciprocal antibody competition assays.
  • In brief, in a reciprocal competition experiment it is investigated whether two (or more) specific binding agents inhibit the binding of one another to the same antigen or epitope. If say antibodies A and B are investigated for binding to the same epitope. Both these antibodies will compete for binding if they bind to the same epitope. Binding to the same epitope is present if antibody A at equimolar concentration reduces binding of B by at least by 20% and vice versa.
  • As the skilled artisan appreciates competition may be assessed in different assay set-ups.
  • Preferably the Biacore® system, see above, is used. Binding of an antibody under investigation to the same epitope as bound by MAB M-R10Z8E9 is present if the antibody under investigation at equimolar concentration reduces the binding of MAB M-R10Z8E9 to human IgG by 20% or more and if MAB M-R10Z8E9 reduces the binding of said antibody to human IgG by 20% or more.
  • MAB M-R10Z8E9 is used as the antibody binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of the experimental animal in a method according to the present invention.
  • As mentioned above, the therapeutic antibody detected in a method according the present invention is a human or a humanized monoclonal antibody. The therapeutic antibody used in a method according to the present invention comprises the epitope as bound by MAB M-R10Z8E9.
  • The present invention relates to the use of an antibody which is binding to a human or humanized therapeutic monoclonal antibody and not binding to the immunoglobulin of an experimental animal for measuring the concentration of total, active, or antigen-bound therapeutic antibody in a sample obtained from an experimental animal. The antibody used in such method is the antibody MAB M-R10Z8E9.
  • The following examples, references, and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims.
    • Description of the Figures
    • Figure 1
    Detection of total therapeutic antibody The biotinylated monoclonal antibody (MAB<H-Fcγ pan>-M-R10Z8E9-Bi) is bound to a streptavidin-coated microtiter plate (SA-MTP). The therapeutic antibody MAB<IGF-1R> is bound and indirectly detected via digoxigenin-labeled MAB<H-Fcγ pan> M-R10Z8E9-DIG and an anti-digoxigenin horse-radish peroxidase conjugate (PAB<DIG>HRP).
    Figure 2:
    Detection of total therapeutic antibody diluted in buffer The optical densities (ODs) are given for the various concentrations of therapeutic antibody as diluted in PBS-T, 0.5% BSA (w/v).
    Figure 3:
    Detection of total therapeutic diluted in buffer but also containing 5% (v/v) cynomolgus serum The optical densities (ODs) are given for the various concentration of therapeutic antibody as diluted in PBS-T, 0.5% BSA with 5% (v/v) cynomolgus serum.
    Figure 4:
    Detection of active therapeutic antibody via solid-phase antigen This cartoon shows the reagents used in the detection of active therapeutic antibody via a solid-phase bound antigen. In the specific example given biotinylated soluble interleukin 1 receptor (s-IL-1R-Bi) is bound to the wells of a streptavidin-coated microtiter plate (SA-MTP). Active therapeutic antibody binds to the antigen and is indirectly detected via digoxigenylated anti- human antibody (MAB<H-Fcγ pan>M-R10Z8E9-DIG) and anti- DIG-HRP (PAB<DIG>HRP).
    Figure 5:
    Detection of active therapeutic antibody diluted in buffer The optical densities (ODs) are given for the various concentrations of therapeutic antibody as diluted in PBS-T, 0.5% BSA.
    Figure 6:
    Detection of active therapeutic antibody diluted in buffer additionally comprising 5% cynomolgus serum The optical densities (ODs) are given for the various concentration of therapeutic antibody as diluted in PBS-T, 0.5% BSA with 5% cynomolgus serum.
    Figure 7:
    Detection of active therapeutic antibody in a sandwich assay format The biotinylated monoclonal antibody (MAB<H-Fcγ pan>-M- R10Z8E9-Bi) is bound to a streptavidin-coated microtiter plate (SA-MTP). Detection is indirect employing the digoxigenin- labeled antigen (s-IL-1R-DIG) and an anti-digoxigenin horse- radish peroxidase conjugate (PAB<DIG>HRP).
    Figure 8:
    Detection of active therapeutic antibody diluted in buffer via a sandwich assay The optical densities (ODs) are given for the various concentrations of therapeutic antibody as diluted in PBS-T, 0.5% BSA.
    Figure 9:
    Detection of active therapeutic antibody diluted in buffer additionally comprising 5% cynomolgus serum via a sandwich assay The optical densities (ODs) are given for the various concentration of therapeutic antibody as diluted in PBS-T, 0.5% BSA with 5% cynomolgus serum.
    Abbreviations
    • ABTS
    2,2'-Azino-di- [3-ethylbenzthiazoline sulfonate (6)] diammonium salt
    BSA
    bovine serum albumin
    ELISA
    enzyme-linked immunosorbent assay
    Fcγ
    =Fcγ = Fcg = Fcgamma = Fc gamma-fragment of an immunoglobulin
    POD (=HRP)
    horse-radish peroxidase
    IgG
    immunoglobulin G
    DIG (Dig)
    digoxigenin
    MTP
    microtiter plate
    OD
    optical density
    PBS
    phosphate buffered saline
    SDS
    sodium dodecyl sulfate
    MAK (=Mab)
    monoclonal antibody
    PAK (=Pab)
    polyclonal antibody
    RT
    room temperature
    SA
    streptavidin
    T
    Tween®20
    <human IgG>
    antibody against human IgG
    Example 1 Assessment of specificity a) Use of various Anti-human IgG antibodies in an MTP-ELISA
  • A microtiter plate (MTP) (Maxisorb®, Nunc) was coated with monkey (e.g. cynomolgus) and with human serum diluted to 20% in carbonate buffer (pH 9.6), at room temperature (RT) for 1 hour, respectively. After washing 3 times with PBS-Tween®20, all wells of the MTPs were blocked with PBS/3%BSA at room temperature for 1 hour. Then the wells of the MTPs were incubated (1 h; RT) with different anti-human IgG antibodies (un-conjugated, or anti-human IgG antibody horseradish peroxidase (POD) conjugates (see Table 1)). The various anti-human antibodies were used as recommended by the corresponding manufacturer.
  • Wells were washed three times as above. Wells incubated with POD-conjugates were directly processed for enzymatic reaction/detection of bound anti-human immunoglobulin. The other wells were incubated (1 h; RT) as appropriate with anti-Dig-, anti-mouse IgG- or streptavidin-POD-conjugates (all reagents from Roche Diagnostics, Germany) followed by a washing step. The POD comprised in the POD-conjugates catalyzes the color reaction of ABTS substrate. The signal was measured by an ELISA reader at a wavelength of 405 nm (reference wavelength: 490 nm). For every anti-human IgG antibody the ratio of the signal against human antibodies to the signal of cynomolgus sera was calculated. These values were used for evaluation of the specificity of the anti-human IgG antibodies. A high ratio translates to a strong reactivity with human immunoglobulin and at the same time to a low (cross-) reactivity with monkey immunoglobulin. Table 1:
    Reactivity of anti-human antibodies with human and cynomolgus monkey serum
    Antibody Signal in 10% (v/v) HumanSerum Signal in 10 % (v/v) cynomolgus serum Signal Ratio Human/Cynom.
    MAK<Human IgG> MK1A6 // Chemicon # CBL101 (*) 0.743 0.895 0.83
    PAK<Human IgG>-Bi // Dako # E0428 (**) 2.066 1.815 1.14
    MAK<H-Fcγ pan> M-R10Z8E9 - Dig (***) 1.847 0.032 58.63
    MAK<H-Fcγ pan> M-R10Z8E9 (*) 1.779 0.199 8.96
    MAK<Human Agg-IgG>IgM-Dig (***) 1.541 0.700 2.20
    MAK<Human Kappa>R12Z6H9-Dig (***) 1.566 0.720 2.17
    MAK<Hu-IgG> F(ab')2 -HRP // Dianova # 109-066-098 1.401 0.953 1.47
    MAK<Human IgG> HRP // Chemicon # AP 113P 0.973 0.574 1.70
    PAK<Human IgG>F(ab)2-HRP // Dako # P0406 0.513 0.431 1.19
    MAK<Human IgG>-HRP // Boehringer Mannheim (alt) 1.383 0.796 1.74
    Controls :
    <Mouse>-HRP 0.139 0.131 1.07
    <Dig>-HRP 0.029 0.031 0.94
    SA-HRP 0.193 0.288 0.67
    (*) = Detection with <Mouse>-HRP
    (**) = Detection with SA-HRP
    (***) = Detection with <Dig>-HRP
  • The high signal ratio for human serum as compared to cynomolgus serum observed for MAB<H-Fcγ pan>M-R10Z8E9 indicates the high human-specificity of MAB<H-Fcγ pan>M-R10Z8E9. In contrast to MAB<H-Fcγ pan>M-R10Z8E9 all other tested antibodies show a high cross-reactivity.
  • Based on the above encouraging data the cross-reactivity of MAB<H-Fcγ pan>M-R10Z8E9 against other immunoglobulin from other relevant experimental animals was investigated.
  • Wells of a microtiter plate were coated with serum from various experimental animals. The assay was performed as described above, using the MAB<H-Fcγ pan>M-R10Z8E9 as specific anti-human IgG detection reagent.
  • As can be seen from Table 2 MAB<H-Fcγ pan>M-R10Z8E9 exclusively reacts with the immunoglobulin of human serum human IgG or chimpanzee serum respectively.
  • Reactivity of MAB<H-Fcγ pan>M-R10Z8E9 with mouse, rat, dog, monkey and human serum, is shown in Tables 2a and b, respectively Table 2a:
    Detection with MAB<H-Fcγ pan>M-R1 0Z8E9-Dig // <Dig>-POD
    Serum (10% (v/v)) Signal Signal Ratio Human / Animal
    Dog 0.096 19.24
    Rat 0.034 54.32
    CD1-Mouse 0.028 65.96
    NMRI-Mouse 0.065 28.42
    Cynomolgus 0.032 58.63
    Baboon 0.029 63.69
    Rhesus macaque 0.031 60.56
    Marmoset 0.128 14.43
    Chimpanzee 1.865 0.99
    Human 1.847 1.00
    Human IgG (5µg/ml) 1.821 1.01
    Table 2b:
    Detection with anti-mouse IgG POD conjugates
    Serum (10% (v/v)) Signal Signal Ratio Human / Animal
    Cynomolgus 0.199 8.96
    Baboon 0.131 13.63
    Rhesus macaque 0.186 9.59
    Marmoset 0.239 7.46
    Chimpanzee 1.893 0.94
    Human 1.779 1.00
    Human IgG (5µg/ml) 2.105 0.85
    It is interesting to note that in the above indirect detection systems the quality of the final reagent <DIG>-POD or <mouse>-POD used in indirect detection also influences the signal to noise ratio. The skilled artisan will choose a detection reagent with little or no binding to the IgG of an experimental animal.
    • b) Assessing antibody binding/specificity by the Biacore® system
  • All measurements were performed with the Biacore® 2000 instrument using a CM5-chip. Coating of an antibody to this chip was achieved by standard amine coupling. Unless otherwise indicated all incubations were performed in HBS-buffer (HEPES, NaCl, pH 7.4) at 25°C.
  • A saturating amount of MAB<H-Fcγ pan>M-R10Z8E9 and polyclonal anti-human Fcγ antibody (Dianova), respectively, was immobilized by amine coupling on different channels of the same CM5-chip. All animal sera were diluted in HBS buffer containing 1mg/ml CM-dextran at a final concentration of 1%. Binding was analyzed by injection of the 1 in 100 diluted sera and incubation for 60 seconds. Dissociation was measured by washing the chip surface with HBS buffer for 180 seconds. Using Biaevaluation Software from Biacore® the dissociation constant values (=KDiss.) were calculated with a 1:1 Langmuir fitting model. For all animal sera this calculation was based on the assumption that the IgG level is 15 mg/ml. The signal values 80 seconds after start of the injection of the test antibody have been chosen for the comparison of the amount of IgG bound (RU in table 2c and 2d). Table 2c:
    Binding signals [RU] of animal sera to MAB<H-Fcγ pan>M-R10Z8E9 and a polyclonal anti-human-Fcy antiserum
    Sample (Serum) MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ>(Dianova)
    Bound RU KD in M Bound RU KD in M
    Human 2377 1.83 x 10-10 2399 5.64 x 10-10
    Cynomolgus 8 no binding 1929 6.24 x 10-11
    CD1-Mouse 2 no binding 0 no binding
    NMRI Mouse 5 no binding 3 no binding
    Rat 25 no binding 92 5.28 x 10-8
    Dog 634 8.12 x 10-8 925 6.21 x 10-10
    Table 2d:
    Binding signals [RU] of different monkey sera to MAB<H-Fcγ pan>M-R10Z8E9 and a polyclonal anti-human-Fcγ antiserum
    Sample (Serum) MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ>(Dianova)
    Bound RU KDiss. in M Bound RU KDiss. in M
    Human 1274.0 1.77 x 10-10 1854.2 2.81 x 10-11
    Cynomolgus 1 2.9 no binding 1591.9 6.64 x 10-11
    Cynomolgus 2 2.8 no binding 1413.1 5.21 x 10-11
    Cynomolgus 3 6.3 no binding 1899.0 1.15 x 10-10
    Baboon 0 no binding 1209.8 7.33 x 10-11
    Marmoset 5.1 no binding 433.9 1.02 x 10-9
    Chimpanzee 1077.5 2.21 x 10-10 1967.5 1.21 x 10-12
    Rhesus Macaque -2.9 no binding 1409.9 4.86 x 10-11
  • The SPR-analysis (of the different monkey sera) confirms the results seen in the MTP ELISA. MAB<H-Fcγ pan>M-R10Z8E9 does not cross-react with any monkey species. Only the IgG comprised in human and chimpanzee (greater ape) serum is detected. In contrast to the MTP ELISA some binding of dog serum to MAB<H-Fcγ pan>M-R10Z8E9. The relatively high KDiss. for dog IgG (correlating to inferior binding) as compared to human IgG with a KDiss.-gap of more than 100-fold indicates, that this low interaction does not interfere significantly in an immunoassay. This is actually what has been found in the MTP ELISA of Example 1a).
  • In contrast to MAB<H-Fcγ pan>M-R10Z8E9 the polyclonal anti-human Fc antibody shows a high cross-reactivity with sera of dog and all tested monkey species.
    • Example 2 Use of MAB<H-Fcγ pan>M-R10Z8E9 for quantification of total therapeutic antibody
  • Biotinylated MAB<H-Fcγ pan>M-R10Z8E9 or polyclonal antibody directed against human Fc was bound to streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound antibody was removed by washing. Samples/standards, e.g. MAB <IGF-1R> spiked in cynomolgus serum, were simultaneously preincubated with digoxigenylated MAB<H-Fcγ pan>M-R10Z8E9 - DIG) for 1 hour. Afterwards the mixture was added to wells of an SA-MTP coated with the biotinylated <human IgG> antibodies and incubated for 1 hour. After washing the bound digoxingenylated MAB<H-Fcγ pan>M-R10Z8E9 was detected with an anti-digoxigenin-antibody. The POD of the antibody-enzyme conjugates catalyzes the color reaction of ABTS substrate. The signal is measured by Elisa reader at 405 nm wavelength (reference wavelength: 490 nm). Absorbance values of each serum sample were determined in triplicates. Table 3:
    Comparison of standard curve in buffer (PBS-T, 0.5% BSA)
    concentration of MAB<IGF-1R> [ng/ml] signal OD 405 nm
    *MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    10 2.039 1.937
    5 1.109 1.094
    2.5 0.586 0.593
    1.25 0.296 0.326
    0.625 0.170 0.176
    0.313 0.108 0.106
    0.156 0.075 0.068
    0 0.046 0.027
  • As can be seen from Table 3 and Figure 2 both anti-Human Fc-gamma antibodies are suitable for quantification of human antibodies (MAB <IGF-1R>), if spiked into buffer. However, in the presence of monkey IgG's (5% cynomolgus serum) the performance of the ELISA with the polyclonal AB<H-Fcγ> became significantly worse. (Table 4 and Figure 3) Table 4:
    Comparison of standard curves in 5% cynomolgus serum
    concentration of MAB<IL-1R> [ng/ml] signal OD 405 nm
    MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    10 1.990 1.5230
    5 1.057 1.4335
    2.5 0.559 1.4410
    1.25 0.289 1.3840
    0.625 0.166 1.3610
    0.313 0.108 1.3780
    0.156 0.091 1.3170
    0 0.054 1.3870
  • Caused by cross-reactivity of PAB<H-Fcγ> (Dianova) with monkey IgG a true or correct quantification of human IgG in monkey serum is not possible.
    • Example 3 Use of MAB<H-Fcγ pan>M-R10Z8E9 in quantification of active human antibody MAB<IL-1R>
  • Biotinylated soluble human IL-1 receptor (h-IL-1R-Bi) was bound to streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound receptor was removed by washing. Afterwards MAB<IL-1R> spiked in cynomolgus serum was bound to the immobilized human IL-1 receptor. After washing away unbound substances the bound MAB<IL-1R> was detected with a) digoxigenylated monoclonal antibody against human IgG chains (MAB<H-Fcγ pan>M-R10Z8E9-DIG) followed by incubation with a horse-radish peroxidase labeled anti-Digoxigenin-antibody; or with b) polyclonal anti-human Fc antibodies (Dianova) followed by a wash step. The POD comprised in the antibody-enzyme conjugates catalyzes the color reaction of ABTS substrate. The signal is measured by ELISA reader at 405 nm wavelength (reference wavelength: 490 nm). Absorbance values of each serum sample are determined in triplicates. Table 5:
    Detection of total therapeutic antibody
    concentration of MAB<IL-1R> [ng/ml] signal OD 405 nm
    MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    10 1.921 1.682
    5 1.307 0.933
    2.5 0.770 0.489
    1.25 0.424 0.262
    0.625 0.231 0.143
    0.313 0.125 0.084
    0.156 0.074 0.057
    0 0.020 0.031
    Table 6:
    Detection of total therapeutic antibody in cynomolgus Serum
    concentration of MAB<IL-1R> [ng/ml] signal OD 405 nm
    MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    10 1.642 1.789
    5 1.637 1.608
    2.5 1.272 1.400
    1.25 0.755 1.228
    0.625 0.435 1.419
    0.313 0.236 1.331
    0.156 0.128 1.315
    0 0.027 1.332
  • The data given in Tables 5 and 6 and shown in Figures 5 and 6 demonstrate that both anti-human Fc-gamma antibodies are suitable for quantification of active human antibodies (MAB<IL-1R>) spiked into buffer. However in the presence of monkey IgG (5% (v/v) cynomolgus serum) the performance of the ELISA with the polyclonal AB<H-Fcγ> became significantly worse. Caused by cross-reactivity with monkey IgG the sensitivity decreased and the variability increased.
    • Example 4 Use of MAB<H-Fcγ pan>M-R10Z8E9 in quantification of active MAB<IL-1R> in monkey serum
  • Biotinylated MAB<H-Fcγ pan>M-R10Z8E9 or biotinylated polyclonal anti-human IgG directed against human Fc (b) was bound onto the wells of a streptavidin-coated microtiter plates (SA-MTP) in the first step. The excess of unbound antibody was removed by washing. Afterwards the MAB<IL-1R> spiked into cynomolgus serum was bound to the immobilized anti-human antibody. After washing away unbound substances the bound MAB<IL-1R> was detected with digoxigenylated soluble human IL-1 receptor (h-IL-1R-Dig) followed by incubation with a horse-radish peroxidase labeled anti-digoxigenin-antibody. The antibody-enzyme conjugate catalyzes the color reaction of ABTS substrate. The signal is measured by ELISA reader at 405 nm wavelength (reference wavelength: 490 nm). Absorbance values of each serum sample are determined in triplicates.
  • A cartoon exemplifying this test system is shown as Figure 7. Table 7:
    Comparison of the standard curves in buffer (PBS-T, 0.5% BSA)
    concentration of MAB<IL-1R> [ng/ml] signal OD 405 nm
    MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    5 1.824 1.685
    2.5 1.319 1.112
    1.25 0.837 0.702
    0.625 0.497 0.413
    0.313 0.277 0.229
    0.156 0.159 0.132
    0 0.025 0.032
    Table 8:
    Comparison of the standard curves in 5% cynomolgus serum
    concentration of MAB<IL-1R> [ng/ml] signal OD 405 nm
    MAB<H-Fcγ pan>M-R10Z8E9 PAB<H-Fcγ> (Dianova)
    5 1.635 0.805
    2.5 1.179 0.460
    1.25 0.707 0.278
    0.625 0.421 0.163
    0.313 0.231 0.101
    0.156 0.136 0.070
    0 0.026 0.04
  • If the therapeutic antibody is diluted in PBS-T with 5% BSA both anti-human antibodies work (cf. Table 7 and Figure 8). However, in the presence of monkey IgG (5% cynomolgus serum) the performance of the ELISA using the polyclonal AB<H-Fcγ> is poor. The signal out-put is much lower despite the same amount of therapeutic antibody present, as shown in Table 8 and Figure 9. Caused by cross-reactivity with monkey IgG the assay performance depends on the total amount and composition of monkey IgG, which can vary from animal to animal and from time-point to time-point.
    • List of References
    • Carter, P., et al., Proc. Natl. Acad. Sci. USA, 89 (1992) 4285-4289
    • Chothia, C., et al., J. Mol. Biol. 196 (1987) 901-917
    • Clackson, T., et al., Nature 352 (1991) 624-628
    • Colowick, S. P., Caplan, N.O. (eds.), Methods in Enzymology, Academic Press
    • Computer program "Align 2" by Genentech, Inc., United States Copyright Office, Washington, DC 20559, December 10, 1991
    • EP-A 0 061 888
    • Jones, P.T., et al., Nature 321 (1986) 522-525
    • Koehler, G., et al., Nature 256 (1975) 495-497
    • Marks, J.D., et al., J. Mol. Biol. 222 (1991)581-597
    • Presta, L.G., et al., J. Immunol. 151 (1993) 2623-2632
    • Presta, L.G., Curr. Op. Struct. Biol. 2 (1992) 593-596
    • Riechmann, L., et al., Nature 332 (1988) 323-327
    • Sims, M.J., et al., J. Immunol. 151 (1993) 2296-2308
    • Tijssen, P., "Practice and theory of enzyme immunoassays", R.H. Burdon and v. P.H. Knippenberg (eds.), Elsevier, Amsterdam, 1990, pp. 221-278; especially pp. 43-78
    • US 2003/0068664
    • US 5,821,337
    • US 4,816,567
    • Verhoeyen, M., et al., Science 239 (1988) 1534-1536
    • WO 93/21319

Claims (5)

  1. A method of detecting a human or humanized therapeutic monoclonal antibody which is intended for use in a human being in a sample obtained from an experimental animal comprising the steps of
    a) providing the sample to be analyzed,
    b) incubating said sample with an antibody binding to said therapeutic antibody and not binding to the immunoglobulin of said experimental animal,
    c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound therapeutic antibody, and
    d) correlating the complex formed in (b) or (c) to the concentration of said therapeutic antibody,
    wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708.
  2. The method according to claim 1, wherein total therapeutic antibody is detected.
  3. The method according to claim 1, wherein active therapeutic antibody is detected.
  4. The method according to claim 1, wherein therapeutic antibody is detected which is bound to its antigen.
  5. Use of an antibody which is binding to a human or humanized therapeutic monoclonal antibody which is intended for use in a human being and not binding to the immunoglobulin of an experimental animal for measuring the concentration of total, active, or antigen-bound therapeutic antibody in a sample obtained from an experimental animal, wherein said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof, and wherein said antibody binding to the therapeutic antibody and not binding to the immunoglobulin of the experimental animal is the antibody deposited in DSM ACC 2708.
EP05824356.9A 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal Active EP1853921B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05824356.9A EP1853921B2 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal
EP10155679A EP2237041A1 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030545 2004-12-23
EP05824356.9A EP1853921B2 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal
PCT/EP2005/013849 WO2006066912A2 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10155679A Division-Into EP2237041A1 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal
EP10155679.3 Division-Into 2010-03-05

Publications (3)

Publication Number Publication Date
EP1853921A2 EP1853921A2 (en) 2007-11-14
EP1853921B1 EP1853921B1 (en) 2011-03-23
EP1853921B2 true EP1853921B2 (en) 2021-07-21

Family

ID=34927934

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05824356.9A Active EP1853921B2 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal
EP10155679A Withdrawn EP2237041A1 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10155679A Withdrawn EP2237041A1 (en) 2004-12-23 2005-12-22 Detection of a therapeutic antibody in an experimental animal

Country Status (15)

Country Link
US (1) US7955806B2 (en)
EP (2) EP1853921B2 (en)
JP (2) JP4664377B2 (en)
KR (1) KR100950635B1 (en)
CN (1) CN101088014B (en)
AT (1) ATE503187T1 (en)
AU (2) AU2005318407B2 (en)
BR (1) BRPI0519354B8 (en)
CA (1) CA2589054C (en)
DE (1) DE602005027127D1 (en)
ES (1) ES2360369T5 (en)
MX (1) MX2007006895A (en)
RU (1) RU2393483C2 (en)
SG (1) SG164389A1 (en)
WO (1) WO2006066912A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506659B (en) * 2006-09-12 2012-12-12 弗·哈夫曼-拉罗切有限公司 Anti-drug antibody assay
ES2428876T3 (en) 2006-09-12 2013-11-12 F. Hoffmann-La Roche Ag Antipharmaceutical Antibody Assay
JP5634405B2 (en) * 2008-10-07 2014-12-03 ユィロス・パテント・アクチボラグＧｙｒｏｓ Ｐａｔｅｎｔ ＡＢ Semi-sequential assay for the detection of analytes in samples
WO2010052344A2 (en) 2008-11-10 2010-05-14 Novartis Ag Antibodies to modified human igf-1/e peptides
SG2014014823A (en) * 2009-10-19 2014-07-30 Hoffmann La Roche Non-cross-reactive anti igg antibodies
RU2603284C2 (en) 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг ANTIBODIES AGAINST HUMAN IgG1
KR102084805B1 (en) 2012-03-08 2020-03-04 에프. 호프만-라 로슈 아게 Multiplexed chromatography-immunoassay method for the characterization of circulating immune complexes
EP2885639B1 (en) 2012-08-17 2019-04-10 MorphoSys AG Complex-specific antibodies and antibody fragments and their use
EP2986990B1 (en) 2013-03-20 2018-08-15 F.Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum
JP6985572B2 (en) 2015-11-09 2021-12-22 国立大学法人京都工芸繊維大学 Single-chain antibody screening method and single-chain antibody
CN107703310B (en) * 2017-10-11 2019-08-30 潍坊医学院附属医院 A kind of experimental implementation system for mouse immune antiboidy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4870003A (en) * 1987-06-15 1989-09-26 Coulter Corporation Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans
US4816067A (en) * 1988-06-20 1989-03-28 Gte Products Corporation Process for producing fine spherical particles
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP2000516594A (en) 1996-07-26 2000-12-12 スミスクライン・ビーチャム・コーポレイション Improved treatment of immune cell-mediated systemic diseases
US6525174B1 (en) * 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
US6413783B1 (en) * 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
JP2000304750A (en) * 1999-04-16 2000-11-02 Fuji Photo Film Co Ltd Luminous label immunoassay and its analysis element
IT1315254B1 (en) * 1999-11-05 2003-02-03 Diesse Diagnostica Senese Spa METHOD FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF IGC-CLASS ANTI-BUMPERS
AUPR617901A0 (en) 2001-07-06 2001-08-02 Pacmab Pty Ltd Method for treating multiple myeloma
US7718387B2 (en) 2001-09-20 2010-05-18 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
JP4636225B2 (en) 2002-11-30 2011-02-23 司甫 横山 Test reagent kit

Also Published As

Publication number Publication date
JP2008525766A (en) 2008-07-17
MX2007006895A (en) 2007-06-26
CA2589054C (en) 2010-11-02
AU2005318407A1 (en) 2006-06-29
AU2005318407B2 (en) 2009-11-05
BRPI0519354B1 (en) 2020-06-09
JP2011039072A (en) 2011-02-24
WO2006066912A9 (en) 2007-02-22
CN101088014A (en) 2007-12-12
BRPI0519354A2 (en) 2009-01-20
KR100950635B1 (en) 2010-04-01
JP4664377B2 (en) 2011-04-06
CN101088014B (en) 2012-10-03
US7955806B2 (en) 2011-06-07
BRPI0519354B8 (en) 2021-07-27
RU2007128103A (en) 2009-01-27
CA2589054A1 (en) 2006-06-29
ATE503187T1 (en) 2011-04-15
SG164389A1 (en) 2010-09-29
ES2360369T3 (en) 2011-06-03
DE602005027127D1 (en) 2011-05-05
EP2237041A1 (en) 2010-10-06
RU2393483C2 (en) 2010-06-27
WO2006066912A3 (en) 2006-08-10
EP1853921B1 (en) 2011-03-23
EP1853921A2 (en) 2007-11-14
KR20070086642A (en) 2007-08-27
AU2010200299A1 (en) 2010-02-18
US20080102474A1 (en) 2008-05-01
ES2360369T5 (en) 2021-12-13
WO2006066912A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
EP1853921B2 (en) Detection of a therapeutic antibody in an experimental animal
US9957331B2 (en) Non-cross-reactive anti IgG antibodies
US9766251B2 (en) Anti-human IgG1 antibody
US20140349323A1 (en) Anti-drug antibody assay

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070723

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100215

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005027127

Country of ref document: DE

Date of ref document: 20110505

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005027127

Country of ref document: DE

Effective date: 20110505

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2360369

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110603

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110624

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20110323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110623

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110725

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E011442

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110723

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: MORPHOSYS AG

Effective date: 20111222

26 Opposition filed

Opponent name: NOVARTIS AG

Effective date: 20111223

Opponent name: MORPHOSYS AG

Effective date: 20111222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005027127

Country of ref document: DE

Effective date: 20111222

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111231

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110323

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

R17C First examination report despatched (corrected)

Effective date: 20100215

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLAH Information related to despatch of examination report in opposition + time limit modified

Free format text: ORIGINAL CODE: EPIDOSCORE2

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PLBC Reply to examination report in opposition received

Free format text: ORIGINAL CODE: EPIDOSNORE3

PLAP Information related to despatch of examination report in opposition + time limit deleted

Free format text: ORIGINAL CODE: EPIDOSDORE2

PLAT Information related to reply to examination report in opposition deleted

Free format text: ORIGINAL CODE: EPIDOSDORE3

PLAY Examination report in opposition despatched + time limit

Free format text: ORIGINAL CODE: EPIDOSNORE2

PLAP Information related to despatch of examination report in opposition + time limit deleted

Free format text: ORIGINAL CODE: EPIDOSDORE2

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20210721

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602005027127

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2360369

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20211213

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221214

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231121

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231124

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231121

Year of fee payment: 19

Ref country code: IE

Payment date: 20231123

Year of fee payment: 19

Ref country code: HU

Payment date: 20231204

Year of fee payment: 19

Ref country code: FR

Payment date: 20231122

Year of fee payment: 19

Ref country code: FI

Payment date: 20231121

Year of fee payment: 19

Ref country code: DE

Payment date: 20231121

Year of fee payment: 19

Ref country code: AT

Payment date: 20231123

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231121

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240102

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240101

Year of fee payment: 19